Fulltext

Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study

Ageno W 1 , Casella IB 2 , Chee KH 3 , Schellong S 4 , Schulman S 5 , Singer DE 6 Show all authors , Desch M 7 , Tang W 8 , Voccia I 9 , Zint K 7 , Goldhaber SZ 10

Affiliations 

  • 1 Department of Medicine and Surgery, University of Insubria, Via Guicciardini 9, 21100, Varese, Italy. [email protected]
  • 2 University of São Paulo, São Paulo, Brazil
  • 3 University of Malaya, Kuala Lumpur, Malaysia
  • 4 Städtisches Klinikum Dresden, Dresden, Germany
  • 5 Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, ON, Canada
  • 6 Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
  • 7 Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
  • 8 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
  • 9 Boehringer Ingelheim Canada, Burlington, ON, Canada
  • 10 Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
J Thromb Thrombolysis, 2021 Apr;51(3):561-570.
PMID: 32851572 DOI: 10.1007/s11239-020-02239-9

Abstract

In randomized clinical trials (RCTs) of nonvitamin K antagonist oral anticoagulants (NOACs) for acute venous thromboembolism (VTE), ~ 12-13% of patients were elderly and ~ 26% had mild-to-moderate renal impairment. Observational studies are not restricted by the selection and treatment criteria of RCTs. In this ancillary analysis of the RE-COVERY DVT/PE global observational study, we aimed to describe patient characteristics, comorbidities, and anticoagulant therapy for subgroups of age (

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications